3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
40
Breast Neoplasms
12
Prostatic Neoplasms
11
Fallopian Tube Neoplasms
10
Pancreatic Neoplasms
7
Neoplasms
7
Endometrial Neoplasms
7
Glioblastoma
6
Neoplasm Metastasis
5
Carcinoma, Ovarian Epithelial
5
Triple Negative Breast Neoplasms
4
Lung Neoplasms
4
Glioma
4
Small Cell Lung Carcinoma
3
Mesothelioma
3
Cystadenocarcinoma, Serous
3
Cholangiocarcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Recurrence
2
Mesothelioma, Malignant
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Uveal Melanoma
1
Interventions
Temozolomide
61
Radiotherapy
25
Bevacizumab
21
Magnetic Resonance Spectroscopy
20
Irinotecan
18
Filgrastim
15
Carboplatin
15
Carmustine
11
Surgical Procedures, Operative
10
Etoposide
9
antineoplaston AS 2-1
8
antineoplaston A10
8
Specimen Handling
8
sargramostim
7
Radiation
7
Peripheral Blood Stem Cell Transplantation
7
Everolimus
7
Biopsy
7
Vincristine
6
Radiotherapy, Intensity-Modulated
6
Procarbazine
6
O(6)-benzylguanine
6
Erlotinib Hydrochloride
6
Topotecan
5
Melphalan
5
Magnetic Resonance Imaging
5
Lomustine
5
Genetic Therapy
5
Cyclophosphamide
5
Aminolevulinic Acid
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Astrocytoma
×
niraparib
×
Clear all
NCT05297864
2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2
Terminated
15 enrolled
13 charts